In this study, the integration of these two methods not only identified the differences in the gut microbiota of CRC patients with different CEA levels but also revealed the mechanism of the interaction between the gut microbiota and the tumor immune micro-environment, which effectively fills the gap in the study of the mechanism of the CEA levels and the progression of CRC. The gene discussed is CEACAM5; the disease is colorectal carcinoma.